Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 2 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER versus SAVAYSA.
HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin), Xa, and others, thereby preventing thrombus formation and extension.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
25,000 units in 250 mL D5W (100 units/mL) continuous IV infusion at 20,000-40,000 units/24 hours; adjust based on aPTT.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
30-150 minutes (dose-dependent, saturable); mean 60-90 min. Prolonged in hepatic/renal impairment and pulmonary embolism.
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Primarily renal (40-60% as unchanged drug) and reticuloendothelial system; small amount biliary/fecal. Clearance is saturable.
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category A/B
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor